Clinion

Executive Summary

Clinion is an India-based digital health company that provides an AI-driven eClinical platform covering the entire clinical trial lifecycle. Founded in 2014 and headquartered in Bangalore, the company employs 200-500 people. Its proprietary suite integrates machine learning for tasks such as CDASH mapping, medical coding, remote source data verification, and generative AI for protocol drafting. This enables sponsors and CROs to accelerate studies, reduce costs, and improve data quality across multiple therapeutic areas including oncology, cardiology, infectious diseases, vaccines, and neurology. By addressing key pain points in clinical trials—such as slow enrollment, data inconsistencies, and high operational costs—Clinion positions itself as a valuable partner in the growing decentralized and eClinical market. The company operates in a highly competitive and expanding segment, with increasing demand for digital solutions to streamline clinical development. Clinion’s platform approach, covering everything from protocol generation to AI-assisted CSR creation, offers a comprehensive value proposition. While the company has not disclosed funding or valuation details, its sustained operation since 2014 suggests steady growth. Key upcoming catalysts include potential strategic partnerships with leading CROs or pharmaceutical companies, a possible Series A or B funding round to accelerate expansion, and the launch of enhanced AI modules or integration with new therapeutic areas. Given the tailwinds in digital health and clinical trial innovation, Clinion is well-positioned to capture market share.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with Major CRO/Pharma60% success
• Q4 2026Series A or B Funding Round50% success
• Q2 2026Launch of New AI Module or Therapeutic Expansion70% success